Evidence map›Paper›PMID 35962445›Full record

ArticlePilot and feasibility studies2022

Prostate cancer-Exercise and Metformin Trial (Pre-EMpT): study protocol for a feasibility factorial randomized controlled trial in men with localised or locally advanced prostate cancer.

Lucy McGeagh, Luke A Robles, Raj Persad, Edward Rowe, Amit Bahl, Jonathan Aning, Anthony Koupparis, Paul Abrams, Claire Perks, Jeffrey Holly and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pilot and feasibility studies, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Experiences implementing a Radiation therapist-led oncology prehabilitation program during COVID-19.Technical innovations & patient support in radiation oncology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Lucy McGeagh *NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.
Luke A Robles *NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0003-2882-9868
Raj PersadBristol Urological Institute, North Bristol NHS Trust, Bristol, UK.
Edward RoweBristol Urological Institute, North Bristol NHS Trust, Bristol, UK.
Amit BahlBristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Jonathan AningBristol Urological Institute, North Bristol NHS Trust, Bristol, UK.
Anthony KoupparisBristol Urological Institute, North Bristol NHS Trust, Bristol, UK.
Paul AbramsBristol Urological Institute, North Bristol NHS Trust, Bristol, UK.
Claire PerksInsulin-like Growth Factors and Metabolic Endocrinology Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Jeffrey HollyInsulin-like Growth Factors and Metabolic Endocrinology Group, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Lyndsey JohnsonClinical Research Centre, North Bristol NHS Trust, Bristol, UK.
Constance ShiridzinomwaClinical Research Centre, North Bristol NHS Trust, Bristol, UK.
Amarnath ChallapalliBristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Ellie ShinglerNIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.
Hilary TaylorNIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.
Jon OxleyDepartment of Cellular Pathology, North Bristol NHS Trust, Bristol, UK.
Meda SanduNIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.
Richard M Martin *NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.
J Athene Lane *NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK. Athene.Lane@bristol.ac.uk.
North Bristol NHS Trust · GBUniversity Hospitals Bristol NHS Foundation Trust · GBUniversity of Bristol · GBOxford Brookes University · GB

Funding

NIHR Biomedical Research Centres Competition 2016 BRC-1215-20011
6 · The paper itself

Abstract

backgroundEvidence from observational studies have shown that moderate intensity physical activity can reduce risk of progression and cancer-specific mortality in participants with prostate cancer. Epidemiological studies have also shown participants taking metformin to have a reduced risk of prostate cancer. However, data from randomised controlled trials supporting the use of these interventions are limited. The Prostate cancer-Exercise and Metformin Trial examines that feasibility of randomising participants diagnosed with localised or locally advanced prostate cancer to interventions that modify physical activity and blood glucose levels. The primary outcomes are randomisation rates and adherence to the interventions over 6 months. The secondary outcomes include intervention tolerability and retention rates, measures of insulin-like growth factor I, prostate-specific antigen, physical activity, symptom-reporting, and quality of life.

methodsParticipants are randomised in a 2 × 2 factorial design to both a physical activity (brisk walking or control) and a pharmacological (metformin or control) intervention. Participants perform the interventions for 6 months with final measures collected at 12 months follow-up. DISCUSSION: Our trial will determine whether participants diagnosed with localised or locally advanced prostate cancer, who are scheduled for radical treatments or being monitored for signs of cancer progression, can be randomised to a 6 months physical activity and metformin intervention. The findings from our trial will inform a larger trial powered to examine the clinical benefits of these interventions.

trial registrationProstate Cancer Exercise and Metformin Trial (Pre-EMpT) is registered on the ISRCTN registry, reference number ISRCTN13543667 . Date of registration 2nd August 2018-retrospectively registered. First participant was recruited on 11th September 2018.

Indexed as

Active surveillanceFeasibility randomised controlled trialLocalisedLocally advancedMetforminPhysical activityProstate cancerProstatectomyRadiotherapy

Identifiers

PMID35962445
PMCPMC9372971
OpenAlexW4291148807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.